Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
biotech
life sciences
national blog main
national top stories
5
×
roche
5
×
boston
boston blog main
boston top stories
deals
fda
clinical trials
genentech
europe top stories
san francisco blog main
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceuticals
avapritinib
billy dunn
biogen
biopharma
blueprint medicines
boehringer ingelheim
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
cstone pharmaceuticals
daniel o'day
dicerna pharamceuticals
drug prices
drug pricing
duchenne
eli lilly
europe blog main
european medicines agency
evrysdi
fisogatinib
flatiron health
foundation medicine
What
roche
5
×
drug
fda
medicine
approval
billion
gene
intended
medicines
pay
recently
team
therapy
acquire
agreed
approved
atrophy
betting
big
biopharma
blueprint
broad
cancer
candidate
caught
causing
confidence
currently
daily
deal
dicerna
didn’t
disease
duchenne
evrysdi
eye
foundation
friday
gain
genentech
Language
unset
Current search:
roche
×
photo
×
" national top stories "
×
roche
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine